Allergan Coverage Initiated by Analysts at Credit Suisse (AGN)
Research analysts at Credit Suisse began coverage on shares of Allergan (NYSE:AGN) in a report released on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.
Allergan (NYSE:AGN) traded down 1.31% on Tuesday, hitting $88.96. 2,264,543 shares of the company’s stock traded hands. Allergan has a 52 week low of $81.33 and a 52 week high of $116.45. The stock’s 50-day moving average is $89.82 and its 200-day moving average is $96.99. The company has a market cap of $26.408 billion and a P/E ratio of 28.99.
Allergan (NYSE:AGN) last released its earnings data on Wednesday, July 31st. The company reported $1.22 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.20 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the company posted $1.07 earnings per share. Allergan’s revenue was up 10.2% compared to the same quarter last year. Analysts expect that Allergan will post $4.76 EPS for the current fiscal year.
AGN has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Allergan in a research note to investors on Monday, September 16th. They now have a $93.00 price target on the stock. Separately, analysts at JMP Securities cut their price target on shares of Allergan from $115.00 to $110.00 in a research note to investors on Thursday, August 1st. They now have a “market outperform” rating on the stock. Eleven equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Allergan presently has an average rating of “Buy” and a consensus price target of $107.16.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.